Targeted HER2 therapy has greatly improved the survival of HER2-positive breast cancer patients [100, 101], and combination therapy has increased efficacy in the neoadjuvant setting [102, 103] and improved survival in the metastatic setting [104, 105]. Here, ERBB2 is linked to breast carcinoma.